Facts | NexPlasmaGen
page-template,page-template-full_width,page-template-full_width-php,page,page-id-15338,bridge-core-2.6.4,qode-page-transition-enabled,ajax_fade,page_not_loaded,,qode-theme-ver-24.9,qode-theme-bridge,disabled_footer_top,qode_header_in_grid,qode-wpml-enabled,wpb-js-composer js-comp-ver-7.0,vc_responsive


Breast Cancer Recurrence

Breast Cancer Recurrence

Worldwide over 1 million women annually undergo breast conserving surgeries as a breast cancer therapy, whereby the benefits of combining radiotherapy following a local surgical lumpectomy procedure has demonstrated improved outcomes with reduced local recurrence rate.


Nevertheless, a 15% locoregional recurrence rate of breast cancer is reported within 10 years, in addition to the concerns frequently arising about the pathologic margin status post lumpectomy. In both cases, mastectomy is the preferred procedure, preventing women from preserving their breast while adding to the morbidity and cost of patient care.



Surgery Augmented by Cold Plasma

Surgery Augmented by Cold Plasma

Most mainline anti-cancer therapies, including radio/chemo therapies operate primarily via cellular oxidative stress, to induce cancer cells death without affecting healthy tissue. Similarly, Cold Plasma is an ionized non-thermal gas that generates various reactive species inducing similar cellular oxidative stress.


Yet, Cold Plasma has the unique ability to deliver these reactive species directly at the surgical margin in the tumor bed, during surgery, addressing the concerns arising from traditional therapies that damage surrounding organs and generate side effects.


NexPlasmaGen is designing a device that would enable a surgeon to kill the remaining cancer cells responsible for high rates of locoregional recurrence.

Patented Cold Plasma Device

Patented Cold Plasma Device

NexPlasmaGen has designed and patented a cold plasma device (US 7,608,839 and WO2021/022371 A1) that can selectively produce and deliver the most relevant plasma species for a given type of cancer, to produce the optimal cellular oxidative stress inducing cancer cell death.


NexPlasmaGen design is uniquely positioned to enable the reproducible “therapeutic” effect desired in the treatment of cancers, since it creates a controlled plasma environment that does not alter plasma properties at the treatment site.

Our peer-reviewed scientific papers with the CPJ technology and previous versions of it:


-Jean-Sébastien Boisvert, Julie Lafontaine, Audrey Glory, Sylvain Coulombe, and Philip Wong (2020) “Comparison of Three Radio-Frequency Discharge Modes on the Treatment of Breast Cancer Cells in Vitro”, IEEE Transactions on radiation and plasma medical sciences, Vol.4, No.5. (link to article)


– Julie Lafontaine, Jean-Sébastien Boisvert, Audrey Glory, Sylvain Coulombe, and Philip Wong (2020), “Synergy between Non-Thermal Plasma with Radiation Therapy and Olaparib in a Panel of Breast Cancer Cell Lines”, Cancers, 12, 348; doi:10.3390/cancers12020348. (link to article)


-Leduc M., Guay D., Leask R.L., Coulombe S. (2010). “Effect of Non-Thermal Plasmas on DNA and Mammalian Cells”, Plasma Proc. Poly., 7, 899-909. (link to article)


-Leduc M., Guay D., Leask R.L., Coulombe S. (2009). “Cell Permeabilization Using a Non-Thermal Plasma”, New J. of Phys., 11, 1-12. (link to article)


-Leduc M., Coulombe S. and Leask R.L. (2009). “Atmospheric Pressure Plasma Jet Deposition of Patterned Polymer Film for Cell Culture,” IEEE Trans. Plasma Sci. (Special Issue on Atmospheric-Pressure Plasmas: Science and Applications) 37, 927-933. (link to article)


-Léveillé V. and Coulombe S. (2006). “Electrical Probe Calibration and Power Calculation for a Miniature 13.56 MHz Plasma Source”, Meas. Sci. Technol. 17, 3027-3032. (link to article)


-Léveillé V. and Coulombe S. (2006). “Atomic Oxygen Production and Exploration of Reaction Mechanisms in a He-O2 Atmospheric Pressure Glow Discharge Torch”, Plasma Proc. Poly. 3(8), 587- 596.(link to article)


-Yonson S., Coulombe S., Léveillé V. and Leask R. L. (2006). “Cell Treatment and Surface Functionalization Using a Miniature Atmospheric Pressure Glow Discharge Plasma Torch,” J. Phys. D: Appl. Phys. 39, 3508-3513. (link to article)


-Coulombe S., Léveillé V., Yonson S. and Leask R. (2006). “Miniature Atmospheric Pressure Glow Discharge Torch (APGD-t) for Local Biomedical Applications,” Pure & Applied Chemistry, 78(6), 1137-1146. (link to article)


-Léveillé V. and Coulombe S., (2005). “Design and Preliminary Characterization of a Miniature Pulsed RF APGD Torch with Downstream Injection of the Source of Reactive Species”, Plasma Sources Science and Technology, 14, 467-476.(link to article)